-
1
-
-
84855343477
-
Projected life expectancy of people with HIV according to timing of diagnosis
-
Nakagawa F, Lodwick RK, Smith CJ etal. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012; 26: 335-343.
-
(2012)
AIDS
, vol.26
, pp. 335-343
-
-
Nakagawa, F.1
Lodwick, R.K.2
Smith, C.J.3
-
2
-
-
0038714245
-
Highly active antiretroviral therapy and cardiovascular complications in HIV-infected patients
-
Barbaro G, Klatt EC. Highly active antiretroviral therapy and cardiovascular complications in HIV-infected patients. Curr Pharm Des 2003; 9: 1475-1481.
-
(2003)
Curr Pharm Des
, vol.9
, pp. 1475-1481
-
-
Barbaro, G.1
Klatt, E.C.2
-
3
-
-
0036840147
-
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel
-
Schambelan M, Benson CA, Carr A etal. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002; 31: 257-275.
-
(2002)
J Acquir Immune Defic Syndr
, vol.31
, pp. 257-275
-
-
Schambelan, M.1
Benson, C.A.2
Carr, A.3
-
4
-
-
33750994354
-
Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients
-
Orlando G, Meraviglia P, Cordier L etal. Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients. HIV Med 2006; 7: 549-557.
-
(2006)
HIV Med
, vol.7
, pp. 549-557
-
-
Orlando, G.1
Meraviglia, P.2
Cordier, L.3
-
6
-
-
34250671221
-
Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease
-
Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-2512.
-
(2007)
J Clin Endocrinol Metab
, vol.92
, pp. 2506-2512
-
-
Triant, V.A.1
Lee, H.2
Hadigan, C.3
Grinspoon, S.K.4
-
7
-
-
67649403401
-
Metabolic abnormalities associated with HIV infection and antiretroviral therapy
-
Fichtenbaum CJ. Metabolic abnormalities associated with HIV infection and antiretroviral therapy. Curr Infect Dis Rep 2009; 11: 84-92.
-
(2009)
Curr Infect Dis Rep
, vol.11
, pp. 84-92
-
-
Fichtenbaum, C.J.1
-
8
-
-
77953365087
-
Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection
-
Moyle G, Moutschen M, Martínez E etal. Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection. AIDS Rev 2010; 12: 3-14.
-
(2010)
AIDS Rev
, vol.12
, pp. 3-14
-
-
Moyle, G.1
Moutschen, M.2
Martínez, E.3
-
9
-
-
0032551258
-
Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
-
Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351: 1881-1883.
-
(1998)
Lancet
, vol.351
, pp. 1881-1883
-
-
Carr, A.1
Samaras, K.2
Chisholm, D.J.3
Cooper, D.A.4
-
10
-
-
0033065070
-
Lipodystrophy in patients naive to HIV protease inhibitors
-
Madge S, Kinloch-de-Loes S, Mercey D, Johnson MA, Weller IV. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS 1999; 13: 735-737.
-
(1999)
AIDS
, vol.13
, pp. 735-737
-
-
Madge, S.1
Kinloch-de-Loes, S.2
Mercey, D.3
Johnson, M.A.4
Weller, I.V.5
-
11
-
-
84871234436
-
Inflammation, coagulation and cardiovascular disease in HIV-infected individuals
-
Duprez DA, Neuhaus J, Kuller LH etal. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS ONE 2012; 7: e44454.
-
(2012)
PLoS ONE
, vol.7
-
-
Duprez, D.A.1
Neuhaus, J.2
Kuller, L.H.3
-
12
-
-
73549088748
-
Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study
-
Obel N, Farkas DK, Kronborg G etal. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med 2010; 11: 130-136.
-
(2010)
HIV Med
, vol.11
, pp. 130-136
-
-
Obel, N.1
Farkas, D.K.2
Kronborg, G.3
-
13
-
-
75649093029
-
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study
-
Worm SW, Sabin C, Weber R etal. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201: 318-330.
-
(2010)
J Infect Dis
, vol.201
, pp. 318-330
-
-
Worm, S.W.1
Sabin, C.2
Weber, R.3
-
14
-
-
1642403331
-
Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men
-
Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-2486.
-
(2003)
AIDS
, vol.17
, pp. 2479-2486
-
-
Mary-Krause, M.1
Cotte, L.2
Simon, A.3
Partisani, M.4
Costagliola, D.5
-
15
-
-
79959748876
-
Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database
-
Durand M, Sheehy O, Baril J-G, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database. J Acquir Immune Defic Syndr 2011; 57: 245-253.
-
(2011)
J Acquir Immune Defic Syndr
, vol.57
, pp. 245-253
-
-
Durand, M.1
Sheehy, O.2
Baril, J.-G.3
Lelorier, J.4
Tremblay, C.L.5
-
16
-
-
20844463037
-
Treating morphologic and metabolic complications in HIV-infected patients on antiretroviral therapy. A consensus statement of an advisory committee of the International Association of Physicians in AIDS Care
-
Fichtenbaum CJ, Hadigan CM, Kotler DP etal. Treating morphologic and metabolic complications in HIV-infected patients on antiretroviral therapy. A consensus statement of an advisory committee of the International Association of Physicians in AIDS Care. IAPAC Mon 2005; 11: 38-46.
-
(2005)
IAPAC Mon
, vol.11
, pp. 38-46
-
-
Fichtenbaum, C.J.1
Hadigan, C.M.2
Kotler, D.P.3
-
18
-
-
0037456351
-
Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection
-
Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 702-710.
-
(2003)
N Engl J Med
, vol.348
, pp. 702-710
-
-
Bozzette, S.A.1
Ake, C.F.2
Tam, H.K.3
Chang, S.W.4
Louis, T.A.5
-
19
-
-
13944282290
-
Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients
-
Iloeje UH, Yuan Y, L'italien G etal. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 2005; 6: 37-44.
-
(2005)
HIV Med
, vol.6
, pp. 37-44
-
-
Iloeje, U.H.1
Yuan, Y.2
L'italien, G.3
-
20
-
-
77955296288
-
Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4
-
Lang S, Mary-Krause M, Cotte L etal. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170: 1228-1238.
-
(2010)
Arch Intern Med
, vol.170
, pp. 1228-1238
-
-
Lang, S.1
Mary-Krause, M.2
Cotte, L.3
-
21
-
-
84897372057
-
Prevalence and type of drug-drug interactions involving antiretrovirals in patients attending a specialist outpatient clinic in Kampala, Uganda
-
Seden K, Merry C, Lamorde M etal. Prevalence and type of drug-drug interactions involving antiretrovirals in patients attending a specialist outpatient clinic in Kampala, Uganda. J Int AIDS Soc 2012; 15: 18335.
-
(2012)
J Int AIDS Soc
, vol.15
, pp. 18335
-
-
Seden, K.1
Merry, C.2
Lamorde, M.3
-
22
-
-
80051688679
-
Ageing with HIV: medication use and risk for potential drug-drug interactions
-
Marzolini C, Back D, Weber R etal. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother 2011; 66: 2107-2111.
-
(2011)
J Antimicrob Chemother
, vol.66
, pp. 2107-2111
-
-
Marzolini, C.1
Back, D.2
Weber, R.3
-
23
-
-
84862169774
-
Using computer-based monitoring and intervention to prevent harmful combinations of antiretroviral drugs in the New York State AIDS Drug Assistance Program
-
Gonzalez CJ, Rivera CA, Martin RJ, Mergian GA, Cruz H, Agins BD. Using computer-based monitoring and intervention to prevent harmful combinations of antiretroviral drugs in the New York State AIDS Drug Assistance Program. Jt Comm J Qual Patient Saf 2012; 38: 269-276.
-
(2012)
Jt Comm J Qual Patient Saf
, vol.38
, pp. 269-276
-
-
Gonzalez, C.J.1
Rivera, C.A.2
Martin, R.J.3
Mergian, G.A.4
Cruz, H.5
Agins, B.D.6
-
24
-
-
84897402763
-
-
HIV-Druginteractions.org [Internet]. [cited Jan 20]. Available at:(accessed 2 January 2013).
-
HIV-Druginteractions.org [Internet]. [cited 2013 Jan 20]. Available at: http://www.hiv-druginteractions.org/ (accessed 2 January 2013).
-
(2013)
-
-
-
25
-
-
77953596007
-
Aging and HIV infection: a comparison between older HIV-infected persons and the general population
-
Onen NF, Overton ET, Seyfried W etal. Aging and HIV infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials 2010; 11: 100-109.
-
(2010)
HIV Clin Trials
, vol.11
, pp. 100-109
-
-
Onen, N.F.1
Overton, E.T.2
Seyfried, W.3
-
26
-
-
45249121177
-
Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4
-
Zhou S-F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008; 9: 310-322.
-
(2008)
Curr Drug Metab
, vol.9
, pp. 310-322
-
-
Zhou, S.-F.1
-
27
-
-
23044448423
-
Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs
-
Boffito M, Acosta E, Burger D etal. Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antivir Ther (Lond) 2005; 10: 469-477.
-
(2005)
Antivir Ther (Lond)
, vol.10
, pp. 469-477
-
-
Boffito, M.1
Acosta, E.2
Burger, D.3
-
28
-
-
15244350599
-
Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients
-
Fellay J, Marzolini C, Decosterd L etal. Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur J Clin Pharmacol 2005; 60: 865-873.
-
(2005)
Eur J Clin Pharmacol
, vol.60
, pp. 865-873
-
-
Fellay, J.1
Marzolini, C.2
Decosterd, L.3
-
29
-
-
0347319044
-
Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications
-
Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004; 57: 6-14.
-
(2004)
Br J Clin Pharmacol
, vol.57
, pp. 6-14
-
-
Mangoni, A.A.1
Jackson, S.H.D.2
-
30
-
-
77954206288
-
Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir
-
Crawford KW, Spritzler J, Kalayjian RC etal. Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. AIDS Res Hum Retroviruses 2010; 26: 635-643.
-
(2010)
AIDS Res Hum Retroviruses
, vol.26
, pp. 635-643
-
-
Crawford, K.W.1
Spritzler, J.2
Kalayjian, R.C.3
-
31
-
-
84865831511
-
A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experience
-
Waters L, Patterson B, Scourfield A etal. A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experience. Int J STD AIDS 2012; 23: 546-552.
-
(2012)
Int J STD AIDS
, vol.23
, pp. 546-552
-
-
Waters, L.1
Patterson, B.2
Scourfield, A.3
-
32
-
-
34247105737
-
Older age and the response to and tolerability of antiretroviral therapy
-
Silverberg MJ, Leyden W, Horberg MA, Delorenze GN, Klein D, Quesenberry CP Jr. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med 2007; 167: 684-691.
-
(2007)
Arch Intern Med
, vol.167
, pp. 684-691
-
-
Silverberg, M.J.1
Leyden, W.2
Horberg, M.A.3
Delorenze, G.N.4
Klein, D.5
Quesenberry Jr, C.P.6
-
33
-
-
77953913058
-
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study
-
Smith C, Sabin CA, Lundgren JD etal. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24: 1537-1548.
-
(2010)
AIDS
, vol.24
, pp. 1537-1548
-
-
Smith, C.1
Sabin, C.A.2
Lundgren, J.D.3
-
34
-
-
84907817074
-
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012
-
Williams I, Churchill D, Anderson J etal. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012; 13 (Suppl 2): 1-85.
-
(2012)
HIV Med
, vol.13
, Issue.SUPPL. 2
, pp. 1-85
-
-
Williams, I.1
Churchill, D.2
Anderson, J.3
-
35
-
-
84862812703
-
Cholesterol is associated with the presence of a lipid core in carotid plaque of asymptomatic, young-to-middle-aged African Americans with and without HIV infection and cocaine use residing in inner-city Baltimore, Md., USA
-
Du J, Wasserman BA, Tong W etal. Cholesterol is associated with the presence of a lipid core in carotid plaque of asymptomatic, young-to-middle-aged African Americans with and without HIV infection and cocaine use residing in inner-city Baltimore, Md., USA. Cerebrovasc Dis 2012; 33: 295-301.
-
(2012)
Cerebrovasc Dis
, vol.33
, pp. 295-301
-
-
Du, J.1
Wasserman, B.A.2
Tong, W.3
-
36
-
-
49849094871
-
Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women
-
Cook JA, Burke-Miller JK, Cohen MH etal. Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS 2008; 22: 1355-1363.
-
(2008)
AIDS
, vol.22
, pp. 1355-1363
-
-
Cook, J.A.1
Burke-Miller, J.K.2
Cohen, M.H.3
-
37
-
-
0035198762
-
Principles and practice of HIV-protease inhibitor pharmacoenhancement
-
Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001; 2: 105-113.
-
(2001)
HIV Med
, vol.2
, pp. 105-113
-
-
Moyle, G.J.1
Back, D.2
-
38
-
-
0032710215
-
Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy
-
Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS 1999; 13: 2311-2312.
-
(1999)
AIDS
, vol.13
, pp. 2311-2312
-
-
Kakuda, T.N.1
Brundage, R.C.2
Anderson, P.L.3
Fletcher, C.V.4
-
39
-
-
17144388269
-
Do oestrogen receptors play a role in the pathogenesis of HIV-associated lipodystrophy?
-
Barzon L, Zamboni M, Pacenti M etal. Do oestrogen receptors play a role in the pathogenesis of HIV-associated lipodystrophy? AIDS 2005; 19: 531-533.
-
(2005)
AIDS
, vol.19
, pp. 531-533
-
-
Barzon, L.1
Zamboni, M.2
Pacenti, M.3
-
40
-
-
34447268893
-
Impact of genetic polymorphisms on the risk of lipid disorders in patients on anti-HIV therapy
-
Bonnet E, Genoux A, Bernard J, Fauvel J, Massip P, Perret B. Impact of genetic polymorphisms on the risk of lipid disorders in patients on anti-HIV therapy. Clin Chem Lab Med 2007; 45: 815-821.
-
(2007)
Clin Chem Lab Med
, vol.45
, pp. 815-821
-
-
Bonnet, E.1
Genoux, A.2
Bernard, J.3
Fauvel, J.4
Massip, P.5
Perret, B.6
-
41
-
-
79952335046
-
Plasma levels of soluble CD14 independently predict mortality in HIV infection
-
Sandler NG, Wand H, Roque A etal. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203: 780-790.
-
(2011)
J Infect Dis
, vol.203
, pp. 780-790
-
-
Sandler, N.G.1
Wand, H.2
Roque, A.3
-
42
-
-
60649109560
-
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients
-
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22: F17-F24.
-
(2008)
AIDS
, vol.22
-
-
-
43
-
-
79958833758
-
Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era
-
Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis 2011; 53: 84-91.
-
(2011)
Clin Infect Dis
, vol.53
, pp. 84-91
-
-
Bedimo, R.J.1
Westfall, A.O.2
Drechsler, H.3
Vidiella, G.4
Tebas, P.5
-
44
-
-
84870292477
-
No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis
-
Ding X, Andraca-Carrera E, Cooper C etal. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr 2012; 61: 441-447.
-
(2012)
J Acquir Immune Defic Syndr
, vol.61
, pp. 441-447
-
-
Ding, X.1
Andraca-Carrera, E.2
Cooper, C.3
-
45
-
-
0037202854
-
Protease inhibitors and cardiovascular outcomes in patients with HIV-1
-
Holmberg SD, Moorman AC, Williamson JM etal. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360: 1747-1748.
-
(2002)
Lancet
, vol.360
, pp. 1747-1748
-
-
Holmberg, S.D.1
Moorman, A.C.2
Williamson, J.M.3
-
46
-
-
0037103407
-
Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?
-
Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30: 471-477.
-
(2002)
J Acquir Immune Defic Syndr
, vol.30
, pp. 471-477
-
-
Klein, D.1
Hurley, L.B.2
Quesenberry Jr, C.P.3
Sidney, S.4
-
47
-
-
84861674709
-
A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity
-
Moyle GJ, Andrade-Villanueva J, Girard P-M etal. A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity. Antivir Ther (Lond) 2012; 17: 689-700.
-
(2012)
Antivir Ther (Lond)
, vol.17
, pp. 689-700
-
-
Moyle, G.J.1
Andrade-Villanueva, J.2
Girard, P.-M.3
-
48
-
-
0037083174
-
Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1
-
Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002; 185: 456-462.
-
(2002)
J Infect Dis
, vol.185
, pp. 456-462
-
-
Wolf, K.1
Tsakiris, D.A.2
Weber, R.3
Erb, P.4
Battegay, M.5
-
49
-
-
33751515147
-
CD4+ count-guided interruption of antiretroviral treatment
-
El-Sadr WM, Lundgren JD, Neaton JD etal. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296.
-
(2006)
N Engl J Med
, vol.355
, pp. 2283-2296
-
-
El-Sadr, W.M.1
Lundgren, J.D.2
Neaton, J.D.3
-
50
-
-
0037380408
-
Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens
-
Woerle HJ, Mariuz PR, Meyer C etal. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 2003; 52: 918-925.
-
(2003)
Diabetes
, vol.52
, pp. 918-925
-
-
Woerle, H.J.1
Mariuz, P.R.2
Meyer, C.3
-
51
-
-
10244259281
-
The effects of HIV protease inhibitors on carbohydrate and lipid metabolism
-
Lee GA, Rao MN, Grunfeld C. The effects of HIV protease inhibitors on carbohydrate and lipid metabolism. Curr Infect Dis Rep 2004; 6: 471-482.
-
(2004)
Curr Infect Dis Rep
, vol.6
, pp. 471-482
-
-
Lee, G.A.1
Rao, M.N.2
Grunfeld, C.3
-
52
-
-
19344373051
-
Antiretroviral Therapy and the Prevalence and Incidence of Diabetes Mellitus in the Multicenter AIDS Cohort Study
-
Brown TT. Antiretroviral Therapy and the Prevalence and Incidence of Diabetes Mellitus in the Multicenter AIDS Cohort Study. Arch Intern Med 2005; 165: 1179-1184.
-
(2005)
Arch Intern Med
, vol.165
, pp. 1179-1184
-
-
Brown, T.T.1
-
53
-
-
0024432794
-
Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid
-
Miners JO. Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid. Clin Pharmacokinet 1989; 17: 327-344.
-
(1989)
Clin Pharmacokinet
, vol.17
, pp. 327-344
-
-
Miners, J.O.1
-
54
-
-
0031265804
-
Lack of pharmacokinetic interaction between dipyridamole and zalcitabine in rats
-
Abobo CV, Xian Y. Lack of pharmacokinetic interaction between dipyridamole and zalcitabine in rats. Cell Mol Biol (Noisy-le-grand) 1997; 43: 1045-1050.
-
(1997)
Cell Mol Biol (Noisy-le-grand)
, vol.43
, pp. 1045-1050
-
-
Abobo, C.V.1
Xian, Y.2
-
55
-
-
35448967118
-
Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes
-
Janneh O, Jones E, Chandler B, Owen A, Khoo SH. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 2007; 60: 987-993.
-
(2007)
J Antimicrob Chemother
, vol.60
, pp. 987-993
-
-
Janneh, O.1
Jones, E.2
Chandler, B.3
Owen, A.4
Khoo, S.H.5
-
56
-
-
34247256797
-
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently
-
Farid NA, Payne CD, Small DS etal. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007; 81: 735-741.
-
(2007)
Clin Pharmacol Ther
, vol.81
, pp. 735-741
-
-
Farid, N.A.1
Payne, C.D.2
Small, D.S.3
-
57
-
-
58249135635
-
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
-
Collet J-P, Hulot J-S, Pena A etal. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373: 309-317.
-
(2009)
Lancet
, vol.373
, pp. 309-317
-
-
Collet, J.-P.1
Hulot, J.-S.2
Pena, A.3
-
58
-
-
61449265175
-
Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection
-
Silverberg MJ, Leyden W, Hurley L etal. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med 2009; 150: 301-313.
-
(2009)
Ann Intern Med
, vol.150
, pp. 301-313
-
-
Silverberg, M.J.1
Leyden, W.2
Hurley, L.3
-
59
-
-
39549093402
-
A comparison of the effectiveness of lipid-lowering therapy between HIV- and non-HIV-infected subjects with hyperlipidaemia
-
Townsend ML, Hollowell SB, Bhalodia J, Wilson KH, Kaye KS, Johnson MD. A comparison of the effectiveness of lipid-lowering therapy between HIV- and non-HIV-infected subjects with hyperlipidaemia. Int J STD AIDS 2007; 18: 851-855.
-
(2007)
Int J STD AIDS
, vol.18
, pp. 851-855
-
-
Townsend, M.L.1
Hollowell, S.B.2
Bhalodia, J.3
Wilson, K.H.4
Kaye, K.S.5
Johnson, M.D.6
-
60
-
-
79952341800
-
High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial
-
Ganesan A, Crum-Cianflone N, Higgins J etal. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis 2011; 203: 756-764.
-
(2011)
J Infect Dis
, vol.203
, pp. 756-764
-
-
Ganesan, A.1
Crum-Cianflone, N.2
Higgins, J.3
-
61
-
-
79960202601
-
Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients
-
Moore RD, Bartlett JG, Gallant JE. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS ONE 2011; 6: e21843.
-
(2011)
PLoS ONE
, vol.6
-
-
Moore, R.D.1
Bartlett, J.G.2
Gallant, J.E.3
-
62
-
-
0037040378
-
Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047
-
Internet]. Available at:
-
Fichtenbaum CJ, Gerber JG, Rosenkranz SL etal. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS [Internet]. 2002;16 (4) Available at: http://journals.lww.com/aidsonline/Fulltext/2002/03080/Pharmacokinetic_interactions_between_protease.8.aspx.
-
(2002)
AIDS
, vol.16
, Issue.4
-
-
Fichtenbaum, C.J.1
Gerber, J.G.2
Rosenkranz, S.L.3
-
63
-
-
84861830855
-
Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin
-
Samineni D, Desai PB, Sallans L, Fichtenbaum CJ. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. J Clin Pharmacol 2012; 52: 922-931.
-
(2012)
J Clin Pharmacol
, vol.52
, pp. 922-931
-
-
Samineni, D.1
Desai, P.B.2
Sallans, L.3
Fichtenbaum, C.J.4
-
64
-
-
36148941342
-
Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients
-
Van der Lee M, Sankatsing R, Schippers E etal. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther (Lond) 2007; 12: 1127-1132.
-
(2007)
Antivir Ther (Lond)
, vol.12
, pp. 1127-1132
-
-
Van der Lee, M.1
Sankatsing, R.2
Schippers, E.3
-
65
-
-
41149090140
-
Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers
-
Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW. Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr 2008; 47: 570-578.
-
(2008)
J Acquir Immune Defic Syndr
, vol.47
, pp. 570-578
-
-
Kiser, J.J.1
Gerber, J.G.2
Predhomme, J.A.3
Wolfe, P.4
Flynn, D.M.5
Hoody, D.W.6
-
66
-
-
83755225761
-
British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals
-
Asboe D, Aitken C, Boffito M etal. British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals. HIV Med 2011; 13: 1-44.
-
(2011)
HIV Med
, vol.13
, pp. 1-44
-
-
Asboe, D.1
Aitken, C.2
Boffito, M.3
-
67
-
-
84897413604
-
-
NORVIR (Ritonavir). Summary of product characteristics. 26 August 1996 (revised 17 January 2013). Abbott Laoratories Limited, Abbott House, Maidenhead, Berkshire.
-
NORVIR (Ritonavir). Summary of product characteristics. 26 August 1996 (revised 17 January 2013). Abbott Laoratories Limited, Abbott House, Maidenhead, Berkshire.
-
-
-
-
68
-
-
84897422342
-
-
REYATAZ (Atazanavir sulphate). Summary of product characterstics. 2 March 2004 (revised June 2013). Bristol-Squibb Pharmaceuticals Ltd, Bristol Squibb House, Uxbridge, Middlesex.
-
REYATAZ (Atazanavir sulphate). Summary of product characterstics. 2 March 2004 (revised June 2013). Bristol-Squibb Pharmaceuticals Ltd, Bristol Squibb House, Uxbridge, Middlesex.
-
-
-
-
69
-
-
0024216321
-
Amlodipine in elderly hypertensive patients: pharmacokinetics and pharmacodynamics
-
Abernethy DR, Gutkowska J, Lambert MD. Amlodipine in elderly hypertensive patients: pharmacokinetics and pharmacodynamics. J Cardiovasc Pharmacol 1988; 12 (Suppl 7): S67-S71.
-
(1988)
J Cardiovasc Pharmacol
, vol.12
, Issue.SUPPL. 7
-
-
Abernethy, D.R.1
Gutkowska, J.2
Lambert, M.D.3
-
70
-
-
0024463794
-
The pharmacokinetic profile of amlodipine
-
Abernethy DR. The pharmacokinetic profile of amlodipine. Am Heart J 1989; 118 (5 Pt 2): 1100-1103.
-
(1989)
Am Heart J
, vol.118
, Issue.5 PART 2
, pp. 1100-1103
-
-
Abernethy, D.R.1
-
71
-
-
23444446328
-
Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers
-
Glesby MJ, Aberg JA, Kendall MA etal. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin Pharmacol Ther 2005; 78: 143-153.
-
(2005)
Clin Pharmacol Ther
, vol.78
, pp. 143-153
-
-
Glesby, M.J.1
Aberg, J.A.2
Kendall, M.A.3
-
72
-
-
0019402888
-
Fatal bone-marrow suppression associated with captopril
-
El-Makri A, Larabi MS, Kechrid C, Belkahia C, Ben Ayed H. Fatal bone-marrow suppression associated with captopril. Br Med J (Clin Res Ed) 1981; 283: 277-278.
-
(1981)
Br Med J (Clin Res Ed)
, vol.283
, pp. 277-278
-
-
El-Makri, A.1
Larabi, M.S.2
Kechrid, C.3
Belkahia, C.4
Ben Ayed, H.5
-
74
-
-
0032935655
-
Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes
-
Bourrié M, Meunier V, Berger Y, Fabre G. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes. Drug Metab Dispos 1999; 27: 288-296.
-
(1999)
Drug Metab Dispos
, vol.27
, pp. 288-296
-
-
Bourrié, M.1
Meunier, V.2
Berger, Y.3
Fabre, G.4
-
75
-
-
0035753492
-
CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro
-
Hanatani T, Fukuda T, Ikeda M etal. CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro. Pharmacogenomics J 2001; 1: 288-292.
-
(2001)
Pharmacogenomics J
, vol.1
, pp. 288-292
-
-
Hanatani, T.1
Fukuda, T.2
Ikeda, M.3
-
76
-
-
48649085310
-
Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study
-
De Wit S, Sabin CA, Weber R etal. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008; 31: 1224-1229.
-
(2008)
Diabetes Care
, vol.31
, pp. 1224-1229
-
-
De Wit, S.1
Sabin, C.A.2
Weber, R.3
-
77
-
-
0042267283
-
A cautionary tale: fatal lactic acidosis complicating nucleoside analogue and metformin therapy
-
Worth L, Elliott J, Anderson J, Sasadeusz J, Street A, Lewin S. A cautionary tale: fatal lactic acidosis complicating nucleoside analogue and metformin therapy. Clin Infect Dis 2003; 37: 315-316.
-
(2003)
Clin Infect Dis
, vol.37
, pp. 315-316
-
-
Worth, L.1
Elliott, J.2
Anderson, J.3
Sasadeusz, J.4
Street, A.5
Lewin, S.6
-
78
-
-
33846168144
-
Pharmacokinetic interactions with thiazolidinediones
-
Scheen AJ. Pharmacokinetic interactions with thiazolidinediones. Clin Pharmacokinet 2007; 46: 1-12.
-
(2007)
Clin Pharmacokinet
, vol.46
, pp. 1-12
-
-
Scheen, A.J.1
-
79
-
-
38349103468
-
Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus
-
Becker ML, Visser LE, Trienekens PH, Hofman A, van Schaik RHN, Stricker BHC. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin Pharmacol Ther 2008; 83: 288-292.
-
(2008)
Clin Pharmacol Ther
, vol.83
, pp. 288-292
-
-
Becker, M.L.1
Visser, L.E.2
Trienekens, P.H.3
Hofman, A.4
van Schaik, R.H.N.5
Stricker, B.H.C.6
|